NEW YORK, Feb. 16, 2021
/PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or
the "Company") today announced the execution of a Letter of Intent
with Silo Pharma Inc. ("Silo") to grant to AIkido a worldwide, exclusive sublicense for
use of peptide therapy, combined with psilocybin, in the
therapeutic treatment of neuroinflammatory disease in cancer
patients. This Letter of Intent is in addition to the
January 6, 2021, licensing agreement
between AIkido Pharma and Silo and these additional assets expand the
Company's asset base in the area of psilocybin to treat cancer.
The Company notes that there is no assurance that the proposal
will result in a binding agreement with Silo or that the
transaction contemplated by the Letter of
Intent, or any other transaction between the parties, will
be completed. The transaction is subject to customary due
diligence. Consummation of the transaction is necessarily further
subject to entering into a definitive agreement between the parties
containing specific signing and closing terms and conditions yet to
be negotiated.
This press release shall not constitute an offer to sell or the
solicitation of an offer to acquire any securities, nor shall there
be any sale of any securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or other jurisdiction.
About AIkido Pharma Inc.
AIkido Pharma Inc. was
initially formed in 1967 and is a biotechnology company with a
diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of
Texas at Austin and Wake
Forest University. Our diverse pipeline of therapeutics includes
therapies for pancreatic cancer, acute myeloid leukemia (AML) and
acute lymphoblastic leukemia (ALL). In addition, we are constantly
seeking to grow our pipeline to treat unmet medical needs in
oncology. The Company is also developing a broad-spectrum
antiviral platform that may potentially inhibit replication of
multiple viruses including Influenza virus, SARS-CoV (coronavirus),
MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Words such as "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan,"
"intend" or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties, including without
limitation those set forth in the Company's filings with the SEC,
not limited to Risk Factors relating to its business contained
therein. Thus, actual results could be materially different. The
Company expressly disclaims any obligation to update or alter
statements whether as a result of new information, future events or
otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-enters-into-letter-of-intent-with-silo-pharma-for-use-of-psilocybin-and-peptide-therapy-for-cancer-treatment-301228585.html
SOURCE AIkido Pharma Inc.